98.1
136.95 (01.40%)
As of Mar 06, 2024
MODERNA, INC. [MRNA]
As of Feb 23, 2024 | Source: Annual Report to the SEC
Company Overview
Moderna is a leader in the creation of the field of messenger RNA (mRNA) medicine. By working at the intersection of science, technology and health for more than a decade, we have developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.
| Country | United States |
| Headquarters | Cambridge, Massachusetts |
| Phone Number | 6177146500 |
| Industry | Chemicals And Allied Products |
| Employees | 5,600 |
| CEO | St phane Bancel |
| Website | www.modernatx.com |
Key fundamental financials loss of $3,630 million Revenue of $1,831 million Current Reporting Revenue Net Income Profit/Loss Sep 2023 $1,831 million $3,630 million loss Jun 2023 $344 million $1,380 mi...
Key fundamental financials loss of $1,380 million Revenue of $344 million Current Reporting Revenue Net Income Profit/Loss Jun 2023 $344 million $1,380 million loss Mar 2023 $1,862 million $79 million...
Key fundamental financials profit of $79 million Revenue of $1,862 million earnings per share of $0.19 Current Reporting Revenue Net Income Profit/Loss Mar 2023 $1,862 million $79 million profit Sep 2...
Key fundamental financials profit of $79 million earnings per share of $0.19 Revenue of $1,862 million Moderna, Inc. [MRNA] has reported $79 million profit for the fiscal quarter ending Mar 31, 2023 w...
Net Sales: $19,263.00M Moderna, Inc. [MRNA] posted a profit of $8,362.00M, marking a fall of 100.00% for this year. Revenue fell to $19,263.00M this year compared to $18,471,000,000.00M in the previou...
Financial Overview
| Revenue | 6,848 M |
| Operating Revenue | -4,239 M |
| Profits | -4,714 M |
| Net Cash | -289 M |
Management Effectiveness
| Return on Equity | -34.03% |
| Return on Assets | -25.58% |
| Turnover Ratio | 0.31 M |
| EBIT | -4,239 M |
Profit Ratios
| Gross Margin | 2,155 M |
| Operating Margin | -61.9% |
| Profit as % of Revenues | -45.71% |
| Profit as % of Assets | -21.29% |
| Profit as % of Stockholder Equity | -34.03% |
Balance Sheet and Cash Flow Measures
| Total Assets | 18,426 M |
| Total Liabilities | 4,572 M |
| Operating Cash Flow | -3,118 M |
| Investing Cash Flow | 4,206 M |
| Financing Cash Flow | -1,377 M |